Company research / COGT

Cogent Biosciences, Inc. (COGT)

CIK 0001622229 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

Key ratios (year ended 2025-12-31)

-51.7%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-05

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenuen/an/an/an/an/an/a$7.87M$22.50M$9.73M$8.36M
R&D Expense$290.72M$269.78M$232.66M$173.75M$121.63M$55.91M$25.74M$43.71M$38.28M$29.83M
Operating Income-$389.09M-$333.36M-$275.94M-$208.13M-$147.84M-$75.55M-$82.20M-$32.18M-$36.01M-$26.15M
Depreciation & Amortization$2.67M$2.60M$2.50M$2.30M$800.0K$147.0K$720.0K$1.29M$1.32M$1.17M
EBITDA-$386.42M-$330.76M-$273.44M-$205.83M-$147.04M-$75.40M-$81.48M-$30.89M-$34.68M-$24.98M
Net Income-$377.18M-$328.94M-$255.86M-$192.41M-$140.24M-$72.27M-$74.81M-$31.83M-$34.53M-$25.49M
EPS (Diluted)n/a-$2.16-$1.94-$1.94-$1.73-$1.87n/an/an/an/a
Total Assets$834.55M$937.61M$327.90M$313.44M$300.81M$232.09M$250.92M$49.42M$85.93M$49.12M
Total Liabilities$302.16M$301.24M$71.61M$55.63M$45.08M$17.91M$16.25M$17.66M$25.69M$20.81M
Long-Term Debt$223.46M$222.90Mn/an/an/an/an/an/an/an/a
Shareholders' Equity$532.39M$636.37M$256.29M$257.80M$255.74M$214.18M$234.67M$31.76M$60.23M-$48.85M
Cash & Equivalents$181.17M$312.01M$98.17M$53.23M$139.89M$219.68M$242.19M$37.42M$55.67M$28.27M
Operating Cash Flow-$307.55M-$264.44M-$207.79M-$153.62M-$118.64M-$58.76M-$35.85M-$41.51M-$32.49M-$25.84M
Capital Expenditures$1.70M$1.55M$573.0K$2.80M$6.86M$1.72Mn/a$33.0K$549.0K$912.0K
Free Cash Flow-$309.24M-$266.00M-$208.36M-$156.42M-$125.50M-$60.48Mn/a-$41.55M-$33.04M-$26.75M
Shares Outstanding171.60M160.98M110.46M86.12M69.89M43.81M32.35M7.67M30.06M10.20M
Weighted Average Diluted Sharesn/a128.90M103.86M79.66M58.74M38.73Mn/an/an/an/a
EPS (Basic)n/a-$2.16-$1.94-$1.94-$1.73-$1.87n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView